|
|
INI-505/26 SALUS, LJUBLJANA, d.d., Ljubljana Business Report of the joint-stock company SALUS, Ljubljana, d.d. and the SALUS Group for the period January - September 2026 Pursuant to the provisions of the Rules of the Ljubljana Stock Exchange, d.d. Ljubljana, and Articles of the Financial Instrument Market Act (ZTFI-1), the company SALUS, Ljubljana, d.d., Litostrojska cesta 46a, Ljubljana, herby publishes information on the operations of SALUS, Ljubljana, d.d. and the SALUS Group for the period January - September 2026.
Continued double-digit growth
SALUS Group continued to grow across all levels. Revenue increased from EUR 503.9 million to EUR 599.9 million, which is 20.5% higher than in the same period last year. EBITDA increased by 16.2 to EUR 23.7 million. Net profit for the period amounted to EUR 13.8 million, which is 15.5% higher than in the same period of 2025, when it amounted to EUR 11.9 million.
The results were driven by an increased volume of business, agency representations, and the contributions of companies integrated into the Group in recent years. These now represent a significant part of the Group’s operations and, since their integration, have consistently contributed to revenue growth and profitability.
The Group has expanded its portfolio of partnerships by adding new international pharmaceutical partners, while also extending its cooperation with existing partners to additional countries. It has introduced several new medicines to markets in the region, including treatments for multiple sclerosis and rare diseases, as well as products for cardiovascular prevention and pain relief. In the Baltic states and Bulgaria, the Group has expanded its activities in the field of treating rare diseases.
The Group’s growth is accompanied by initiatives to enhance operational efficiency and further digitalize business operations a key objective of its current strategy. During the first nine months of 2026, the Group implemented or initiated several projects aimed at boosting productivity, optimizing logistics processes, and improving inventory management. Notable examples include the consolidation of warehousing and logistics operations for the MEDITRADE, and the gradual centralization of supply for SANOLABOR stores.
The SALUS Group builds its growth on both organic business expansion and targeted acquisitions. It is expanding its presence in the CEE region by developing local capabilities and infrastructure, and by strengthening its teams with experienced professionals. The Group enables growth for each company that joins the Group through shared infrastructure, regional reach and relationships with international manufacturers.
First choice for commercialization and distribution in the CEE region
The results confirm the Group's direction of development. “Results are exceeding our expectations and reaffirming that our strategy works. We remain a reliable supplier of medicines to pharmacies and hospitals, we equip healthcare institutions and laboratories with modern medical technology, and in SANOLABOR stores we strive to provide the best possible shopping experience. A growing number of companies see us as their partner for entering the CEE region, which brings us closer to our goal of becoming the first choice for commercialization and distribution in the region. Some of the new partnerships and medicines launched in recent months will be reflected in upcoming months, which means we are entering next year on a solid foundation. We are thankful to our employees and our partners, with whom we work together to find solutions and ensure that medicines, medical devices and equipment reaches everyone who needs it, " said Žiga Hieng, President of the Management Board of SALUS, Ljubljana, d.d.
Looking ahead
For the 2026 financial year, SALUS Group expects to generate approximately EUR 812 million in net sales revenue, EUR 19 million in operating profit from regular operations, EUR 28 million in regular EBITDA and EUR 15.5 million in net profit. The plan follows the Group's strategy, which is built on consolidating its position in the Slovenian market and internationalising its operations across the CEE region.
This announcement will be available on our website from 16 November 2026 until the expiry of the legally prescribed publication period. Management Board
Date: 16.11.2026
|
|